Chronic Fatigue Syndrome (CFS)
Chronic Fatigue Syndrome (CFS), also known as Myalgic Encephalomyelitis (ME), is a complex, long-term condition characterised by extreme fatigue that does not improve with rest and can worsen with physical or mental activity. The condition affects multiple body systems, including the nervous, immune, and endocrine systems.
The exact cause of CFS/ME is unknown, but it is believed to be triggered by a combination of genetic, environmental, and immunological factors. Researchers from the University of Edinburgh found that in England, the lifetime prevalence of ME/CFS might be as high as 0.92% among women and 0.25% among men—equating to an estimated total of around 404,000 individuals affected. According to the CDC, approximately 1.3% of adults in the U.S. had ME/CFS in 2021-2022, with women being more frequently diagnosed than men. Globally, the prevalence of ME/CFS varies, with estimates ranging from 0.2% to 2.8%.
References
Andretta, A., Dias, E., Mello, R., Batista, L., & Schieferdecker, M. E. M. (2019). Magnesium and Fibromyalgia: A Literature Review. Advances in Rheumatology, 59(1), 55
Castro-Marrero, J., Cordero, M. D., Segundo, M. J., Sáez-Francàs, N., Calvo, N., Román-Malo, L., ... & Alegre, J. (2015). Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome? Antioxidants & Redox Signaling, 22(8), 679-685.
Castro-Marrero, J., Zaragozá, M.C., Domingo, J.C., Martinez-Martinez, A., Alegre, J. and von Schacky, C., 2018. Low omega-3 index and polyunsaturated fatty acid status in patients with chronic fatigue syndrome/myalgic encephalomyelitis. Prostaglandins, Leukotrienes and Essential Fatty Acids, 139, pp.20-24.
Centers for Disease Control and Prevention (2023) Clinical Overview of ME/CFS. Available at: https://www.cdc.gov/me-cfs/hcp/clinical-overview/index.html (Accessed: 11 October 2024).
Earl, K.E., Sakellariou, G.K., Sinclair, M., Fenech, M., Croden, F., Owens, D.J., Tang, J., Miller, A., Lawton, C., Dye, L. and Close, G.L., 2017. Vitamin D status in chronic fatigue syndrome/myalgic encephalomyelitis: a cohort study from the North-West of England. BMJ open, 7(11), p.e015296.
Maes, M., Mihaylova, I. and De Ruyter, M., 2006. Lower serum zinc in Chronic Fatigue Syndrome (CFS): relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. Journal of affective disorders, 90(2-3), pp.141-147.
Maes, M., Mihaylova, I., Kubera, M., Uytterhoeven, M., Vrydags, N. and Bosmans, E., 2009. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro endocrinology letters, 30(4), pp.470-476.
Russell-Jones, GJ 2022 Functional vitamin B12 deficiency in CFS. Int J. Psychiatry 27 Jul 2022.
Samms, G.L. and Ponting, C.P., 2025. Unequal access to diagnosis of myalgic encephalomyelitis in England. BMC Public Health, 25(1), p.1417.
Tschopp, R., König, R.S., Rejmer, P. and Paris, D.H., 2023. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): A preliminary survey among patients in Switzerland. Heliyon, 9(5).
Vahratian, A., Lin, J.M.S., Bertolli, J. and Unger, E.R., 2023. Myalgic encephalomyelitis/chronic fatigue syndrome in adults: United States, 2021–2022. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.
Witham, M., Kennedy, G., Belch, J., Hill, A., & Khan, F. (2014). Association between vitamin D status and markers of vascular health in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). International Journal of Cardiology, 174(1), 139-140.
Witham, M.D., Adams, F., McSwiggan, S., Kennedy, G., Kabir, G., Belch, J.J.F. and Khan, F., 2015. Effect of intermittent vitamin D3 on vascular function and symptoms in chronic fatigue syndrome–a randomised controlled trial. Nutrition, Metabolism and Cardiovascular Diseases, 25(3), pp.287-294.